Publicaciones en colaboración con investigadores/as de Copenhagen University Hospital (8)

2024

  1. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

    New England Journal of Medicine, Vol. 390, Núm. 4, pp. 301-313

  2. Efficacy of T-cell assays for the diagnosis of primary defects in cytotoxic lymphocyte exocytosis

    Blood, Vol. 144, Núm. 8, pp. 873-887

2023

  1. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)

    Leukemia, Vol. 37, Núm. 6, pp. 1175-1185

2022

  1. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics

    European Journal of Haematology, Vol. 108, Núm. 1, pp. 73-83

2021

  1. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

    Leukemia, Vol. 35, Núm. 6, pp. 1722-1731

2020

  1. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

    Leukemia, Vol. 34, Núm. 8, pp. 2000-2011

2015

  1. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

    Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051

2011

  1. Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)

    Blood, Vol. 118, Núm. 17, pp. 4519-4529